Wednesday, September 27, 2023 |

Gaithersburg’s Emergent BioSolutions lands large federal contract to boost development of Ebola drug

August 2, 2023

Gaithersburg’s Emergent BioSolutions Inc. (NYSE: EBS) has landed a long-term contract with the U.S. Department of Health and Human Resources to scale up manufacturing of a drug designed to treat Ebola. The drug, a monoclonal antibody known as Ebanga, was developed by Miami’s Ridgeback Biotherapeutics and approved by the Food and Drug Administration for the treatment of Ebola in December 2020.

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.